跳到正文
WorldBrand.AI

扶他林的争议事件

以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。

返回词条共 2 条

  1. 2020

    澳大利亚误导性Osteo Gel与Emulgel对比案

    澳大利亚联邦法院认定，诺华和GSK的营销宣传使Voltaren Osteo Gel显得比Voltaren Emulgel更有效，尽管在相关骨关节炎用途上两者本质上是同一种凝胶。法院还指出，Osteo Gel的建议零售价可能高出最多16%。罚款总额为450万澳元，包装随后也作了修改。

    来源

  2. 2020

    澳大利亚联邦法院就 Osteo Gel 营销对 GSK 和诺华处以罚款

    罚款或处罚

    澳大利亚联邦法院下令葛兰素史克支付150万澳元、诺华支付300万澳元。两家公司承认，其2012年至2017年间对 Osteo Gel 的营销违反澳大利亚消费者法；法院认定相关营销误导消费者，使其认为该产品比 Emulgel 更有效。

    品牌回应

    • 道歉 — GSK

      In an affidavit, GSK's head of legal Navaneetha Dilipumakanth apologised for the company's conduct and admitted it had "fallen short of the standards expected of it under the Australian Consumer Law".

    来源摘录

    • GSK and Novartis admitted they had breached Australian consumer law with their marketing of Osteo Gel between 2012 and 2017.
    • In an affidavit, GSK's head of legal Navaneetha Dilipumakanth apologised for the company's conduct and admitted it had "fallen short of the standards expected of it under the Australian Consumer Law".
    • The parties also agreed on the question of penalties and Federal Court Justice Robert Bromwich today ordered GSK pay a fine of $1.5 million and Novartis pay $3 million.
    来源